DexCom, Inc. (NASDAQ:DXCM) Shares Acquired by Signaturefd LLC

Signaturefd LLC lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 30.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,561 shares of the medical device company’s stock after purchasing an additional 1,526 shares during the quarter. Signaturefd LLC’s holdings in DexCom were worth $510,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Cibc World Markets Corp grew its stake in shares of DexCom by 12.4% during the 4th quarter. Cibc World Markets Corp now owns 70,763 shares of the medical device company’s stock worth $5,503,000 after purchasing an additional 7,786 shares during the period. SlateStone Wealth LLC purchased a new position in shares of DexCom during the 4th quarter valued at approximately $205,000. Patten & Patten Inc. TN lifted its position in shares of DexCom by 5.0% during the 4th quarter. Patten & Patten Inc. TN now owns 74,811 shares of the medical device company’s stock valued at $5,818,000 after buying an additional 3,570 shares in the last quarter. Envestnet Portfolio Solutions Inc. lifted its position in shares of DexCom by 30.5% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 16,159 shares of the medical device company’s stock valued at $1,257,000 after buying an additional 3,778 shares in the last quarter. Finally, Natixis Advisors LLC lifted its position in shares of DexCom by 446.6% during the 4th quarter. Natixis Advisors LLC now owns 193,532 shares of the medical device company’s stock valued at $15,051,000 after buying an additional 158,124 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on DXCM shares. Wells Fargo & Company reiterated an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Canaccord Genuity Group increased their target price on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Citigroup increased their target price on DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research report on Tuesday, March 4th. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and increased their target price for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Finally, Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and raised their price objective for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $99.82.

DexCom Stock Up 2.4 %

NASDAQ DXCM opened at $75.11 on Friday. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The business’s fifty day simple moving average is $83.41 and its 200-day simple moving average is $76.92. The firm has a market cap of $29.35 billion, a PE ratio of 52.52, a P/E/G ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, equities analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. This trade represents a 2.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael Jon Brown sold 13,000 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $914,940.00. Following the sale, the executive vice president now directly owns 105,602 shares of the company’s stock, valued at $7,432,268.76. The trade was a 10.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 105,009 shares of company stock valued at $8,044,178. 0.30% of the stock is currently owned by insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.